Selenoproteins containing selenium in the form of selenocysteine are critical for bone remodelling.
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humans and rodents, respectively 18, 19 ; most of these-particularly glutathione peroxidases and thioredoxin reductases-play an important role in maintaining cellular antioxidant homeostasis 20 .
Additionally, some selenoproteins of unknown function (SELENOH, SELENOM, SELENOF, SELENOT, SELENOV, and SELENOW) harbour a thioredoxin-like domain with a CysXXSeCys redox motif (where X is any amino acid), implying that they have an antioxidant function 21 .
Nutritional selenium deficiency or genetic abnormalities in selenoproteins are associated with endocrine defects, including cretinism, thyroid hormone default, osteoarthritis (termed Kashin-Beck disease), and growth retardation caused by delayed bone formation [22] [23] [24] . Selenium status is positively correlated with bone mineral density in healthy aging males 25 and postmenopausal women 26 , and mutations in selenocysteine insertion sequence (SECIS)-binding protein 2 lead to defective selenoprotein biosynthesis, which manifests as delayed skeletal development and linear growth 27 .
Mice deficient in SeCys tRNA, which is required for the biosynthesis of all selenoproteins, and SeCys-rich selenoprotein P, which is responsible for selenium transport and storage, exhibit abnormal skeletal development 28, 29 . Although some studies have suggested a connection between selenium, selenoproteins, and bone metabolism, there are no known selenoproteins to date that participate exclusively in bone remodelling.
In the present study, we identified, through a large-scale mRNA profiling analysis, selenoprotein W (SELENOW) 30 , a protein of unknown function containing a SeCys encoded by UGA at codon 13 whose expression is negatively regulated by RANKL. SELENOW was originally 6 reported as being associated with the white coloration in selenium-deficient regions of calcified cardiomyopathy 30 . Here, we show that SELENOW acts as an osteoclastogenic stimulator and engages in negative feedback to suppress osteoclast differentiation and the pathological shift towards bone disorders.
Results

SELENOW stimulates osteoclastogenesis.
To identify novel genes that are up-or down-regulated during RANKL-induced osteoclastogenesis, we carried out mRNA expression profiling using GeneChip arrays. We identified several genes known to be upregulated [e.g., Calcr (encoding calcitonin receptor), Ctsk (encoding cathepsin K), OSCAR, Itgb3 (encoding integrin β3), c-Fos, and
NFATc1]
31,32 or downregulated (e.g., Id2 and IRF8) 11, 13 by RANKL that positively and negatively regulate osteoclastogenesis, respectively ( Supplementary Fig. 1a, b) . Among the downregulated genes, we focused on SELENOW, a ~10-kDa protein that is ubiquitously expressed, with especially high levels detected in the brain, liver, skeletal muscle, and long bone ( Supplementary Fig. 1c, d ).
SELENOW expression was gradually increased during differentiation of macrophage colonystimulating factor (M-CSF)-induced bone marrow-derived macrophages, which are osteoclast precursors ( Supplementary Fig. 2a ). In contrast, SELENOW levels were decreased from the initiation of RANKL-induced osteoclastogenesis in the presence of M-CSF, despite the increase in expression of several osteoclastic-specific markers, including tartrate-resistant acid phosphatase (TRAP), 7
NFATc1, and OSCAR in differentiating cells (Fig. 1a, Supplementary Fig. 2a ). SELENOW repression was confirmed during the differentiation of RAW264.7 cells into osteoclasts in response to RANKL stimulation ( Supplementary Fig. 2b ). These results indicate that SELENOW downregulation during osteoclastogenesis is dependent on RANKL signalling.
Many studies have reported that binding of RANKL to its cognate receptor RANK on the osteoclast precursor membrane leads to the recruitment of tumour necrosis factor receptor-associated factor (TRAF)6, which mediates downstream signals that promote osteoclastogenesis, involving mitogen-activated protein kinases (MAPKs) and transcription factors such as NF-κB, activator protein (AP)-1, and NFATc1 33, 34 . To clarify the mechanism underlying RANKL-dependent inhibition of SELENOW, we evaluated the regulation of SELENOW expression by factors downstream of RANKL/RANK. Treatment with interferon-γ, which targets TRAF6 for proteasomal degradation 35 , failed to induce RANKL-mediated SELENOW downregulation (Fig. 1b) . This was confirmed by examining the differentiation of TRAF6-deficient osteoclasts (Fig. 1c, Supplementary Fig. 2c ), which indicated that SELENOW expression is inhibited via the RANKL/RANK/TRAF6 axis. Additionally, RANKL-induced SELENOW suppression was enhanced by the MAPK kinase inhibitor PD98059, an effect that was reversed by the p38 inhibitor SB203580 (Fig. 1d) . On the other hand, RANKL-induced To investigate the role of SELENOW in osteoclastogenesis, we silenced and overexpressed it using a lentivirus carrying a short hairpin (sh) RNA and a retroviral gene induction system, respectively. SELENOW knockdown decreased whereas its overexpression increased osteoclast differentiation ( Fig. 1e, f) . However, SELENOW expression was unaltered during osteoblast differentiation and modulating SELENOW levels had no effect on this process or on the expression of osteoblast differentiation markers such as Alp (encoding alkaline phosphatase) and Spp1 (encoding osteopontin) 36 ( Supplementary Fig. 3 ). These results indicate that SELENOW acts as a positive regulator of osteoclast differentiation and this effect differs from the inhibitory effects of other genes that are suppressed by RANKL. Moreover, these observations provide evidence that RANKLdependent repression of SELENOW induces proper osteoclast differentiation. (Fig. 2a) , which was confirmed by the decreased levels of osteoclast markers, including NFATc1, tartrate-resistant acid phosphatase type (Acp)5, and OSCAR (Fig. 2b) . We performed microcomputed tomography (μCT) analysis of trabecular bone in the proximal tibia to analyse the physiological function of SELENOW in bone metabolism, and found that SELENOWdeficient male mice had increased bone mass resulting from increases in trabecular bone volume, number, thickness, and mineral density and decreased trabecular bone separation (Fig. 2c ). There were fewer TRAP-positive osteoclasts on the surface of trabecular bone in SELENOW −/− mice as compared to that in controls; however, the two groups had similar numbers of osteoblasts (Fig. 2d) . SELENOW −/− mice also showed decreases in bone formation rate (BFR) and mineral apposition rate (MAR; Fig. 2e ). These results indicate that the increased bone mass observed in SELENOW −/− mice is caused by a reduction in osteoclast formation.
SELENOW deficiency and overexpression
To further clarify the in vivo function of SELENOW in bone physiology, we generated transgenic mice in which SELENOW gene expression was controlled by the promoter of TRAP, which is highly expressed during osteoclast differentiation 38 . SELENOW was gradually upregulated during differentiation of osteoclast precursors from the transgenic mice (Fig. 3a) . Ectopic expression of SELENOW in osteoclast precursors enhanced osteoclast formation as evidenced by the upregulation of osteoclastogenic genes (Fig. 3b, c) , which is consistent with the observation that retrovirus-induced SELENOW overexpression stimulated osteoclastogenesis (Fig. 1f) . In contrast to the osteopetrotic phenotype of SELENOW −/− mice, SELENOW-overexpressing male transgenic mice showed an osteoporotic phenotype in trabecular and calvarial bone, as determined by μ CT scanning (Fig. 3d, e) .
Histological analysis of bone tissue sections revealed that the transgenic mice had more multinucleated TRAP-positive osteoclasts than wild-type mice, whereas no differences were found in the numbers of osteoblasts (Fig. 3f) . Additionally, TRAP staining of the whole calvaria as well as cross sections revealed enhanced osteoclast formation in transgenic mice (Fig. 3g, h ). The area of the calvarial bone marrow cavity, which is an index of bone resorption activity 39 , and the level of urinary deoxypyridinoline (DPD), a marker of bone resorption 40 , were higher in transgenic as compared to that in wild-type mice (Fig. 3h, i ), corresponding to decreases in BFR and MAR (Fig. 3j) . These results imply that the low bone mass in transgenic mice overexpressing SELENOW is caused by bone resorption due to enhanced osteoclast formation. This is consistent with our in vitro observations that SELENOW-regulated bone remodelling results from a cell-autonomous effect on osteoclast formation.
Thus, the regulation of SELENOW expression allows proper osteoclast formation and may be important for normal bone turnover.
SELENOW stimulates osteoclastogenesis via activation of NF-κB and NFATc1. To clarify the molecular mechanism by which SELENOW regulates osteoclastogenic factors, we examined the activation of signalling cascades in immediate or delayed response to RANKL. We found that SELENOW triggered NF-κB activation-as evidenced by increased degradation of inhibitor of NF-κB (IκBα)-but did not affect MAPK (ERK, p38, and JNK) signalling ( Supplementary Fig. 4 ). In addition, SELENOW promoted the nuclear translocation of cytosolic NF-κB and NFATc1 without altering the expression levels of these proteins (Fig. 4a) . To confirm the stimulatory effect of SELENOW on NF-κB-and NFATc1-dependent transcriptional activity, we assessed the activity of promoters with a binding site for NF-κB or NFATc1. A luciferase reporter assay showed that RANKLdependent NF-κB-and NFATc1-induced promoter activity was increased in SELENOWoverexpressing as compared to control cells (Fig. 4b ). In contrast, there was no change in the activity of a promoter harbouring an AP-1-binding site in SELENOW-overexpressing cells. His-tag pull-down and immunoprecipitation (IP) assays revealed that SELENOW interacted with NF-κB and NFATc1
but not with AP-1 ( Fig. 4c, d ). The known SELENOW interaction partner 14-3-3γ 41,42 also formed a complex with SELENOW and was translocated to the nucleus ( Fig. 4a ), negating the possibility that the above observations were an experimental artefact. To further analyse the interaction between SELENOW and NF-κB or NFATc1, chromatin (Ch)IP was performed using an antibody specific to SELENOW or control IgG; immunoprecipitated DNA was PCR amplified with primers recognizing promoters containing an NF-κB-or NFATc1-binding site 43, 44 . A specific PCR product was detected in DNA from cells exhibiting relatively high levels of SELENOW-including undifferentiated osteoclast precursors ( To evaluate pre-osteoclast fusion-a critical step in the formation of multinucleated osteoclasts 49 -we prepared pre-osteoclasts by culturing osteoclast precursors in medium containing M-CSF and RANKL for 2 days. The rate of cell-cell fusion was increased in SELENOWoverexpressing mononuclear pre-osteoclasts as compared to control cells (Fig. 5a ), which was associated with increased mRNA expression of fusion-associated genes including Itgav and Itgb3
(Supplementary Fig. 5a ; right panel). Accordingly, cell-cell fusion was reduced in SELENOW −/− preosteoclasts relative to control cells (Fig. 5b) , with a corresponding decrease in Itgav and Itgb3 and other fusion-related factors such as DC-STAMP and osteoclast-STAMP (Supplementary Fig. 6a ; left panel). We also observed that SELENOW stimulated osteoclastic bone-resorptive activity (Fig. 5c, d) and suppressed the apoptosis of mature osteoclasts, as evidenced by an increase in the number of mature osteoclasts with a full actin ring and decreases in caspase-9 and -3 activities (Fig. 5e, f) .
Previous results obtained by our group and others have shown that cellular redox status is shifted towards oxidation during osteoclast differentiation, which can lead to spontaneous apoptosis of mature osteoclasts 50, 51 ; meanwhile, SELENOW is thought to function as an antioxidant 52 . To investigate this possibility, we evaluated the change in redox status following osteoclast maturation and examined whether this-and consequently, osteoclast lifespan-is modulated by SELENOW.
Consistent with previous reports, redox status was reduced after mature osteoclast formation (Fig. 5g,   h ). In contrast, mature osteoclasts overexpressing SELENOW showed a marked increase in reduction capacity as compared to control cells (Fig. 5g) . We speculated that the prolonged survival of osteoclasts by SEELENOW overexpression was due in part to their high reduction potential resulting in enhanced bone resorption. The relationship between osteoclast survival and redox status was confirmed by the finding that osteoclast lifespan was extended by treatment with the antioxidant Nacetylcysteine, which enhanced osteoclast reduction capacity (Fig. 5i) . Collectively, our results demonstrate that dysregulation of RANKL-mediated inhibition of SELENOW, which is constitutively expressed during osteoclast differentiation, promotes osteoclast maturation by stimulating preosteoclast fusion and leads to excessive bone resorption as a result of increased osteoclast longevity.
Discussion
The results of this study indicate that TRAF6-independent ERK activation mediates RANKL-induced SELENOW upregulation while TRAF6-dependent p38 activation facilitates RANKL-induced SELENOW downregulation. This raises the question of how SELENOW can be predominantly downregulated during osteoclast differentiation when RANKL-activated ERK and p38-which promote and inhibit SELENOW expression, respectively-are both present. We propose that this is possible because RANKL stimulation induces stronger and longer-lasting activation of p38 than M-CSF stimulation (Supplementary Fig. 2d ). Our results also showed that constitutive expression of investigate the specific role of SELENOW in various bone defects, including bone metastatic and osteoporosis-related cancers, for the development of anti-osteoporotic agents using SELENOW.
Our results indicate that the anti-apoptotic effect of SELENOW in osteoclasts may to be due to an increase in the cellular reduction status. It is presumed that abnormal, constitutive expression of SELENOW can prolong osteoclast survival by creating a reducing environment in cells, resulting in excess bone resorption. However, in normal osteoclastogenesis, the stimulatory action of SELENOW Genetically modified mice. SELENOW −/− C57BL6 mice were generated using TALENs specific to exon 1 of SELENOW as previously described 37 . Genomic DNA was isolated from mouse tail Calvarial bone histomorphometric and bone resorption marker analyses. Three-dimensional images of calvarial bone were constructed based on the μ CT scan and bone indices were estimated.
For analysis of calvarial bone histology, whole and cross-sectioned calvaria were stained with TRAP to visualise the extent of osteoclastogenic activity and to assess the number of mature osteoclasts, respectively. Calvarial bone sections were stained with haematoxylin and eosin and the calvarial marrow cavity was measured using Image-Pro Plus v.6.0 software (Media Cybernetics) to estimate the size of the osteolytic lesion. For biochemical analysis of osteoporosis, urinary DPD, a known bone resorption marker, was measured using a commercial immunoassay kit (MicroVeu DPD Enzyme
Immunoassay; Quidel, San Diego, CA, USA) according to the manufacturer's instructions.
Northern blotting, RT-PCR, quantitative real-time (q)PCR, and immunoblotting. Total RNA was isolated from cells or tissues using TRIzol reagent (Invitrogen). SELENOW mRNA level was evaluated by northern blotting using a [ 32 P]dCTP-labelled DNA probe against SELENOW (5'-TCAAAGAACCCGGTGACCTG-3') according to the conventional capillary method 58 . The 18S and 28S rRNA bands on the denaturing agarose gel stained with acridine orange were photographed and served as a loading control. To assess the mRNA levels of various genes, total RNA was reverse-transcribed into cDNA using random hexamers and a MMLV-RT kit (Invitrogen) and target genes were amplified by RT-PCR using the primers listed in Table S1 . For qPCR analysis, total RNA was reverse transcribed into cDNA with the Superscript First-Strand Synthesis System (Invitrogen) and the reaction was carried out on a 7500 Detection System (Applied Biosystems, Foster City, CA, USA) using the Real-time TaqMan PCR assay kit that included primer sets for NFATc1 (Mm00479445_m1), Cytosolic and nuclear proteins were fractionated as described 57 . Proteins were resolved by SDSpolyacrylamide gel electrophoresis (PAGE) on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane that was probed with primary antibodies. Whole cell extracts to detect SELENOW were separated by SDS-PAGE on a 4%-12% gradient gel (Invitrogen).
Immunoblot analysis of SELENOW in various mouse tissues. Mouse tissues including the heart, liver, lung, kidney, fat, pancreas, spleen, stomach, intestines, skin, skeletal muscle, brain, testis, lymph node, and long bone were washed three times with PBS and cut into small pieces in lysis buffer. After sonication with 30-s pulses on ice, tissue homogenates were centrifuged at 12,000 rpm for 10 min at 4°C. The protein concentration of the supernatant was determined using a detergent-compatible protein assay. Proteins were fractionated by SDS-PAGE on a 4%-12% gradient gel and immunoblotting was performed using an anti-SELENOW antibody. 
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or SELENOW (Novus Biologicals). Osteoclast precursors were cultured with M-CSF alone (d0) or with RANKL for 3 days (d3; left panels). The ChIP assay was performed using the EZ-ChIP kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocols. After IP of chromatin with an antibody against SELENOW or control IgG, PCR was performed using DNA and promoterspecific primers containing the NF-κB-or NFATc1-binding sites listed in Table S1 . 
